These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 22406696)
21. The past and future of neuroprotection in cerebral ischaemic stroke. Shuaib A; Hussain MS Eur Neurol; 2008; 59(1-2):4-14. PubMed ID: 17917451 [TBL] [Abstract][Full Text] [Related]
22. Augmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibition. Jung KH; Chu K; Lee ST; Park HK; Kim JH; Kang KM; Kim M; Lee SK; Roh JK Biochem Biophys Res Commun; 2009 Jan; 378(3):507-12. PubMed ID: 19056343 [TBL] [Abstract][Full Text] [Related]
23. Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. Broussalis E; Killer M; McCoy M; Harrer A; Trinka E; Kraus J Drug Discov Today; 2012 Apr; 17(7-8):296-309. PubMed ID: 22134007 [TBL] [Abstract][Full Text] [Related]
24. Targeting the brain: neuroprotection and neurorestoration in ischemic stroke. Saver JL Pharmacotherapy; 2010 Jul; 30(7 Pt 2):62S-9S. PubMed ID: 20575624 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic neuroprotective effects of XQ-1H in a rat model of permanent focal cerebral ischemia. Yang Q; Fang W; Lv P; Geng X; Li Y; Sha L Pharmacology; 2012; 89(1-2):1-6. PubMed ID: 22178991 [TBL] [Abstract][Full Text] [Related]
30. Targets of cytoprotection in acute ischemic stroke: present and future. Lizasoain I; Cárdenas A; Hurtado O; Romera C; Mallolas J; Lorenzo P; Castillo J; Moro MA Cerebrovasc Dis; 2006; 21 Suppl 2():1-8. PubMed ID: 16651809 [TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia. Lumenta DB; Plesnila N; Kläsner B; Baethmann A; Pruneau D; Schmid-Elsaesser R; Zausinger S Brain Res; 2006 Jan; 1069(1):227-34. PubMed ID: 16378603 [TBL] [Abstract][Full Text] [Related]
32. Experimental studies on ischemic neuroprotection: criteria for translational significance. Bhardwaj A Crit Care Med; 2011 May; 39(5):1230-1. PubMed ID: 21610593 [No Abstract] [Full Text] [Related]
37. Current status of neuroprotective agents in the treatment of acute ischemic stroke. Lutsep HL; Clark WM Curr Neurol Neurosci Rep; 2001 Jan; 1(1):13-8. PubMed ID: 11898495 [TBL] [Abstract][Full Text] [Related]
38. New synthesis and promising neuroprotective role in experimental ischemic stroke of ONO-1714. Pozo-Rodrigálvarez A; Gradillas A; Serrano J; Fernández AP; Martínez-Murillo R; Pérez-Castells J Eur J Med Chem; 2012 Aug; 54():439-46. PubMed ID: 22703704 [TBL] [Abstract][Full Text] [Related]
39. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Philip M; Benatar M; Fisher M; Savitz SI Stroke; 2009 Feb; 40(2):577-81. PubMed ID: 19074479 [TBL] [Abstract][Full Text] [Related]
40. DJ-1 based peptide, ND-13, promote functional recovery in mouse model of focal ischemic injury. Molcho L; Ben-Zur T; Barhum Y; Offen D PLoS One; 2018; 13(2):e0192954. PubMed ID: 29489843 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]